Watchlist Movers: Alliance Data Systems Corporation (NYSE:ADS), Cypress Semiconductor Corporation (NASDAQ:CY), Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Alliance Data Systems Corporation (NYSE:ADS) reported that for Q3 ended Sept. 30, 2014, its earnings topped analysts' expectations, while revenue was in line; the company also updated its guidance for fiscal 2014 and provided outlook on fiscal 2015. The provider of transaction-based, data-driven marketing and loyalty solutions posted Q3 net income of $2.74 per share, compared with the prior-year period's $2.01 per share. Core earnings (a non-GAAP measure) was $3.47 per share versus $2.67 per share in the same quarter the previous year.Revenue was $1.32 billion, up 20% from $1.1 million in the same quarter last year. Analysts polled by Capital IQ were expecting EPS of $3.31 on revenues of $1.33 billion. The company said it remains on track to deliver revenue of $5.3 billion for fiscal 2014; it now sees core EPS of $12.40, up from its initial guidance of $12.00 EPS. The Street view is for revenue of $5.31 billion and EPS of $12.43. For fiscal 2015, Alliance Data Systems Corporation (NYSE:ADS) sees revenue of at least $6.6 billion, and core EPS of $14.80 - $15.00, versus the consensus of $6.03 billion in revenue and $14.56 EPS. Shares closed at $238.68, with a 52-week range of $224.20 - $300.48.Cypress Semiconductor Corporation (NASDAQ:CY) has announced Q3 results that were in line with projections on EPS but fell short of projections on total revenue. The company announced Q3 adjusted EPS of $0.16, up from $0.14 in Q3 2013 and in line with anlyst estimates of $0.16. Total revenue of $187.51 million was down from $188.72 million in Q3 2013 and missed analyst projections of $188.26 million for the quarter. The Q3 revenue increase was led by growth in the company's Memory Products Division (MPD) and Emerging Technologies Division (ETD), with 40% sequential growth to $7.5 million. The revenue growth in MPD and ETD was partially offset by ongoing softness in the handset market. Shares of Cypress Semiconductor Corporation (NASDAQ:CY) are trading within a 52-week range of $8.04 - $11.30.Infinity Pharmaceuticals Inc. (NASDAQ:INFI) said Thursday it has "encouraging" results from a phase 2a trial of its asthma drug duvelisib, aka IPI-145. The drug, taken orally, treats patients with mild, allergic asthma. INFI said patents treated with duvelisib could exhale a greater volume of air than patients treated with a placebo. INFI did report that the "primary endpoint of the study was not met, as it did not reach statistical significance." But INFI added that "multiple secondary clinical endpoints measuring improvements in lung function following duvelisib administration were achieved with statistical significance." Infinity Pharmaceuticals Inc. (NASDAQ:INFI) said that the Phase 2a trial results, in total, demonstrate duvelisib's "proof-of-activity." INFI also reported that it has a phase 2 trial of duvelisib under way for the treatment of rheumatoid arthritis.